nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.0608	0.089	CbGpPWpGaD
Metoclopramide—HTR4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0491	0.0719	CbGpPWpGaD
Metoclopramide—HTR4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0413	0.0604	CbGpPWpGaD
Metoclopramide—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0279	0.0881	CcSEcCtD
Metoclopramide—HTR3A—Ion channel transport—CLCN4—nephrolithiasis	0.0272	0.0398	CbGpPWpGaD
Metoclopramide—HTR3A—Ion channel transport—CLCN5—nephrolithiasis	0.0272	0.0398	CbGpPWpGaD
Metoclopramide—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0204	0.0645	CcSEcCtD
Metoclopramide—DRD3—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0179	0.0263	CbGpPWpGaD
Metoclopramide—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0156	0.0494	CcSEcCtD
Metoclopramide—HTR4—G alpha (s) signalling events—PTH—nephrolithiasis	0.0156	0.0228	CbGpPWpGaD
Metoclopramide—CYP11B2—Biological oxidations—SLC26A1—nephrolithiasis	0.0152	0.0223	CbGpPWpGaD
Metoclopramide—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0152	0.048	CcSEcCtD
Metoclopramide—DRD3—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0151	0.0221	CbGpPWpGaD
Metoclopramide—DRD2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0137	0.0201	CbGpPWpGaD
Metoclopramide—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0134	0.0197	CbGpPWpGaD
Metoclopramide—CYP11B1—Biological oxidations—SLC26A1—nephrolithiasis	0.0131	0.0192	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—SLC26A1—nephrolithiasis	0.0123	0.018	CbGpPWpGaD
Metoclopramide—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.012	0.0378	CcSEcCtD
Metoclopramide—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.012	0.0378	CcSEcCtD
Metoclopramide—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0119	0.0377	CcSEcCtD
Metoclopramide—DRD2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0115	0.0169	CbGpPWpGaD
Metoclopramide—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0113	0.0165	CbGpPWpGaD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00948	0.0139	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00947	0.0139	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00947	0.0139	CbGpPWpGaD
Metoclopramide—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00918	0.029	CcSEcCtD
Metoclopramide—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00906	0.0286	CcSEcCtD
Metoclopramide—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00904	0.0285	CcSEcCtD
Metoclopramide—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00853	0.0269	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00844	0.0124	CbGpPWpGaD
Metoclopramide—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00824	0.0121	CbGpPWpGaD
Metoclopramide—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00816	0.0258	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00812	0.0119	CbGpPWpGaD
Metoclopramide—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.008	0.0253	CcSEcCtD
Metoclopramide—DRD3—GPCRs, Other—CHRM3—nephrolithiasis	0.00797	0.0117	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00772	0.0113	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00772	0.0113	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00764	0.0112	CbGpPWpGaD
Metoclopramide—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00757	0.0239	CcSEcCtD
Metoclopramide—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00729	0.023	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—RGS14—nephrolithiasis	0.00716	0.0105	CbGpPWpGaD
Metoclopramide—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00664	0.021	CcSEcCtD
Metoclopramide—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00657	0.0208	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—RGS14—nephrolithiasis	0.0065	0.00951	CbGpPWpGaD
Metoclopramide—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00641	0.0202	CcSEcCtD
Metoclopramide—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00628	0.0198	CcSEcCtD
Metoclopramide—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00625	0.0197	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—CHRM3—nephrolithiasis	0.00619	0.00905	CbGpPWpGaD
Metoclopramide—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00612	0.0193	CcSEcCtD
Metoclopramide—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00604	0.0191	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00585	0.00856	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00585	0.00856	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00585	0.00855	CbGpPWpGaD
Metoclopramide—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0058	0.0183	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—PTH—nephrolithiasis	0.00566	0.00828	CbGpPWpGaD
Metoclopramide—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00563	0.0178	CcSEcCtD
Metoclopramide—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00558	0.0176	CcSEcCtD
Metoclopramide—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00545	0.0172	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00544	0.00796	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00544	0.00796	CbGpPWpGaD
Metoclopramide—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00521	0.0165	CcSEcCtD
Metoclopramide—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00505	0.0159	CcSEcCtD
Metoclopramide—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00497	0.0157	CcSEcCtD
Metoclopramide—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00496	0.0157	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00485	0.00709	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00485	0.00709	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—DGKH—nephrolithiasis	0.00484	0.00708	CbGpPWpGaD
Metoclopramide—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0152	CcSEcCtD
Metoclopramide—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00464	0.00679	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.0046	0.0145	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—ADCY10—nephrolithiasis	0.00452	0.00661	CbGpPWpGaD
Metoclopramide—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00443	0.014	CcSEcCtD
Metoclopramide—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00441	0.0139	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—DGKH—nephrolithiasis	0.00439	0.00643	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00415	0.00607	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00411	0.013	CcSEcCtD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.00402	0.00589	CbGpPWpGaD
Metoclopramide—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00402	0.00589	CbGpPWpGaD
Metoclopramide—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.004	0.0126	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00388	0.00567	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—RGS14—nephrolithiasis	0.00384	0.00562	CbGpPWpGaD
Metoclopramide—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00382	0.0121	CcSEcCtD
Metoclopramide—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00369	0.0117	CcSEcCtD
Metoclopramide—Rash—Hydrochlorothiazide—nephrolithiasis	0.00352	0.0111	CcSEcCtD
Metoclopramide—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00351	0.0111	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0035	0.00512	CbGpPWpGaD
Metoclopramide—Headache—Hydrochlorothiazide—nephrolithiasis	0.0035	0.011	CcSEcCtD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00346	0.00507	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GRHPR—nephrolithiasis	0.00343	0.00503	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00335	0.00491	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00332	0.00485	CbGpPWpGaD
Metoclopramide—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00331	0.0105	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—PTH—nephrolithiasis	0.0032	0.00468	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CHRM3—nephrolithiasis	0.00318	0.00465	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AGXT—nephrolithiasis	0.00306	0.00448	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.003	0.00439	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00297	0.00434	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GRHPR—nephrolithiasis	0.00296	0.00433	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PTH—nephrolithiasis	0.0029	0.00425	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GRHPR—nephrolithiasis	0.00277	0.00405	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00265	0.00388	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AGXT—nephrolithiasis	0.00264	0.00386	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—RGS14—nephrolithiasis	0.00261	0.00383	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—APRT—nephrolithiasis	0.0026	0.00381	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SLC26A1—nephrolithiasis	0.0026	0.00381	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—DGKH—nephrolithiasis	0.00259	0.0038	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00259	0.0038	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00259	0.00379	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AGXT—nephrolithiasis	0.00247	0.00361	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—RGS14—nephrolithiasis	0.00237	0.00347	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00227	0.00332	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CHRM3—nephrolithiasis	0.00226	0.00331	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—APRT—nephrolithiasis	0.00224	0.00328	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SLC26A1—nephrolithiasis	0.00224	0.00328	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00222	0.00325	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—APRT—nephrolithiasis	0.0021	0.00307	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SLC26A1—nephrolithiasis	0.0021	0.00307	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—PTH—nephrolithiasis	0.00207	0.00302	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—RGS14—nephrolithiasis	0.002	0.00293	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00196	0.00286	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CHRM3—nephrolithiasis	0.00188	0.00274	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AQP1—nephrolithiasis	0.00185	0.00271	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RGS14—nephrolithiasis	0.00182	0.00266	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.00178	0.0026	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—DGKH—nephrolithiasis	0.00177	0.00258	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00173	0.00253	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTH—nephrolithiasis	0.00172	0.00251	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.00169	0.00248	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CHRM3—nephrolithiasis	0.00168	0.00245	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADCY10—nephrolithiasis	0.00165	0.00241	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—DGKH—nephrolithiasis	0.0016	0.00235	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AQP1—nephrolithiasis	0.0016	0.00234	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—PTH—nephrolithiasis	0.00158	0.00231	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	0.00155	0.00226	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AQP1—nephrolithiasis	0.0015	0.00219	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CHRM3—nephrolithiasis	0.00145	0.00211	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RGS14—nephrolithiasis	0.0014	0.00205	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CHRM3—nephrolithiasis	0.00135	0.00198	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—DGKH—nephrolithiasis	0.00135	0.00198	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00132	0.00194	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00128	0.00187	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADCY10—nephrolithiasis	0.00126	0.00185	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	0.00124	0.00181	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—DGKH—nephrolithiasis	0.00123	0.0018	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	0.0012	0.00176	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PTH—nephrolithiasis	0.00117	0.00171	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CHRM3—nephrolithiasis	0.00116	0.0017	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RGS14—nephrolithiasis	0.00107	0.00157	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTH—nephrolithiasis	0.00106	0.00155	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	0.00105	0.00154	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000977	0.00143	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000956	0.0014	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000947	0.00139	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DGKH—nephrolithiasis	0.000947	0.00139	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PTH—nephrolithiasis	0.000894	0.00131	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000887	0.0013	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	0.000875	0.00128	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000868	0.00127	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SPP1—nephrolithiasis	0.000861	0.00126	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTH—nephrolithiasis	0.000811	0.00119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	0.000794	0.00116	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000749	0.0011	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000725	0.00106	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DGKH—nephrolithiasis	0.000725	0.00106	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000709	0.00104	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	0.000709	0.00104	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CHRM3—nephrolithiasis	0.000685	0.001	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000667	0.000976	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTH—nephrolithiasis	0.000626	0.000917	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000567	0.00083	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000567	0.00083	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CHRM3—nephrolithiasis	0.000524	0.000767	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	0.000513	0.000751	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTH—nephrolithiasis	0.000479	0.000701	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTH—nephrolithiasis	0.000469	0.000686	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000404	0.000592	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000366	0.000535	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SPP1—nephrolithiasis	0.000314	0.00046	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SPP1—nephrolithiasis	0.000241	0.000352	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	0.000236	0.000345	CbGpPWpGaD
